LAG3 and acute myeloid leukemia: The AARON study (NCT04913922) will test the safety and tolerability of relatlimab (anti-LAG-3) in combination with AZA and nivolumab in patients with relapsed/refractory AML and newly diagnosed AML, who are aged >65 years.